Crescent Biopharma, Inc. ( (CBIO) ) has released its Q3 earnings. Here is a breakdown of the information Crescent Biopharma, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Crescent Biopharma, Inc. is a biotechnology company focused on developing innovative therapies for cancer patients, primarily operating in the oncology sector with a strong emphasis on bispecific antibodies and antibody-drug conjugates. In its third-quarter 2025 earnings report, Crescent Biopharma highlighted significant advancements in its therapeutic pipeline, particularly with its lead program CR-001, a PD-1 x VEGF bispecific antibody, and the progress of its antibody-drug conjugates, CR-002 and CR-003. The company remains on track to submit an IND for CR-001 by the end of 2025, aiming to initiate a global Phase 1 trial in early 2026. Financially, Crescent reported a net loss of $24.6 million for the quarter, with R&D expenses at $20.3 million and G&A expenses at $5.5 million. The company holds a cash position of $133.3 million, expected to support operations through 2027. Looking ahead, Crescent Biopharma is committed to advancing its pipeline and executing its strategic goals, with management expressing optimism about the potential impact of its therapies on cancer treatment.